The significant enrichment of insulin (hsa04910) and glucagon (hsa04922) signaling pathways emphasizes their central role in glucose regulation and energy response, suggesting dysfunction in these pathways as a critical factor in MASLD development [32]. This evidence concerns the gene GCG and metabolic dysfunction-associated steatotic liver disease.